Your Source for Venture Capital and Private Equity Financings
Select An Article
Back to Archive
Aeglea Biotherapeutics Raises $44M in Series B
AUSTIN, TX, Biopharmaceutical company developing novel treatments for inborn errors of metabolism and therapies targeting tumor metabolism, today announced the closing of a $44 million Series B.
Subscribe to Daily VC Alerts